

# Gene Therapy Market: 2019-2026 - Market Analysis and Forecast

<https://marketpublishers.com/r/GBCD599E6295EN.html>

Date: November 2019

Pages: 255

Price: US\$ 1,999.00 (Single User License)

ID: GBCD599E6295EN

## Abstracts

### REPORT OVERVIEW:

Gene therapy has become one of the most rapidly growing and promising fields in regenerative medicine. As compared to conventional medicine, gene therapy is the single-dose solution for a wide application of diseases, significantly for genetic diseases, neurological, infectious and oncological disorders. Mainly encompasses the use of a viral vector to introduce an intact gene, either directly administered into the patient body (In-vivo) or indirectly via transduction of cells before infusion into the patient body (Ex-vivo), to reconstitute, remove, and modify a harmful gene variant.

The global gene therapy market was valued at \$1,049 million in 2018, and is estimated to reach \$10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.

Factors that drive the market growth involves, Increase in funding for R&D activities pertaining to gene therapy, For instance in 2018 cell and gene therapy companies raised over \$981 Million in venture financing, Moreover in 2018 M&A volume reached to \$18.8 Billion with a increase of 26% from 2017.

Increased in No. of Approved Products, By the end of Q3 2019 there are total 15 approved cell and gene therapy products, In 2017 FDA approves KYMRIA<sup>®</sup>, YESCARTA<sup>®</sup> and LUXTURNA<sup>®</sup>, In 2019 ZOLGENSMA<sup>®</sup>, ZYNTEGLO<sup>®</sup> and COLLATEGENE<sup>®</sup> get market approval in U.S., EU and Japan respectively.

Other factors that boost the market growth involves; increase in government support, ethical acceptance of gene therapy for cancer treatment, rise in prevalence of cancer and increase in awareness regarding the gene therapy.

However, high cost associated with the treatment (KYMRIAH® cost around \$475,000, and LUXTURN A® costs \$425,000 per Eye) and unwanted immune responses are expected to hamper the market growth.

The report also presents detailed quantitative analysis of the current market trends and future estimations from 2018 to 2026.

The forecasts cover 2 Vector Type with 13 Sub categories, 8 Gene Type , 6 Application Type, 4 Regions and 16 Countries.

The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report.

## **KEY FINDINGS:**

The report has the following key findings:

The global gene therapy market accounted for \$1,049 million in 2018 and is estimated to reach \$10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.

The viral vector segment was valued at \$566 million in 2018 and is estimated to reach \$5264 million by 2026, registering a CAGR of 32.1% from 2018 to 2026.

Non-viral vector segment exhibits the highest growth rate in the forecast.

Antigen was the largest contributor among the gene type segments.

The oncological disorders segment currently holds 63% of market share and is expected to continue its dominance in future, follows by the rare disease segment.

North America dominated the global gene therapy market in 2018 and is projected to continue its dominance in the future.

China is expected to grow the highest in the Asia-Pacific region during the forecast period.

**TOPICS COVERED:**

The report covers the following topics:

Market drivers, restraints and opportunities

Porter's Five Forces Analysis

Top Winning Strategies, Top Investment Pockets

Analysis of By Vector Type, Gene Type, and Application Type

CAR T-Cell Applications, Limitations, and Market & Industry Trends

50 Companies Profile, Product Portfolio, and Key Strategies

15 Approved Cell and Gene Therapy Product Profiles

30 gene therapy expected approvals in the phase III clinical trials

Gene Therapy clinical trials analysis from 1989 to 2018

Market analysis and forecasts from 2018 to 2026

**FORECAST SEGMENTATION:**

Market forecasts are provided for each of the following sub-markets and their categories:

**1- By Vector Type**

Viral vector

Adenoviruses

Lentiviruses

Adeno-Associated Virus

Retroviruses

Herpes Simplex Virus

Poxvirus

Vaccinia Virus

Others

Non-viral vector

Naked Plasmid Vectors

Electroporation

Gene Gun

Lipofection

Others

## 2- By Gene Type

Antigen

Cytokine

Tumor Suppressor

Suicide

Deficiency

Growth factors

Receptors

Others

### 3- By Application

Oncological Disorders

Rare Diseases

Cardiovascular Diseases

Neurological Disorders

Infectious disease

Other Diseases

### 4- By Region

North America: USA | Canada | Mexico

Europe: UK | Germany | France | Spain | Italy | Rest of Europe

Asia-Pacific: China | Japan | India | South Korea | Rest of Asia-Pacific

LAMEA: Brazil | South Africa | Rest of LAMEA

## Contents

### **CHAPTER 1: INTRODUCTION**

- 1.1 REPORT DESCRIPTION 17-18
- 1.2 TOPICS COVERED
- 1.3 KEY MARKET SEGMENTS
- 1.4 KEY BENEFITS
- 1.5 RESEARCH METHODOLOGY
- 1.6 TARGET AUDIENCE
- 1.7 COMPANIES MENTIONED 23-25

### **CHAPTER 2: EXECUTIVE SUMMARY**

- 2.1 EXECUTIVE SUMMARY 26-28
- 2.2 CXO PROSPECTIVE

### **CHAPTER 3: MARKET OVERVIEW**

- 3.1 MARKET DEFINITION AND SCOPE
- 3.2 KEY FINDINGS
- 3.3 TOP INVESTMENT POCKETS
- 3.4 TOP WINNING STRATEGIES
  - 3.4.1. Top winning strategies, by year, 2016-2018\*
  - 3.4.2. Top winning strategies, by development, 2016-2018\*(%)
  - 3.4.3. Top winning strategies, by company, 2016-2018\*
- 3.5 TOP PLAYER POSITIONING, BY PIPELINE VOLUME, 2018
- 3.6 PORTERS FIVE FORCES ANALYSIS 37-38
- 3.7 MARKET DYNAMICS
  - 3.6.1 Drivers
    - 3.6.1.1 High investment for R&D activities pertaining to gene therapy
    - 3.6.1.2 Increase in prevalence of cancer
    - 3.6.1.3 Growth in awareness regarding gene therapy
  - 3.6.2 Restrains
    - 3.6.2.1 High cost associated with gene therapies
    - 3.6.2.2 Unwanted immune responses
  - 3.6.3 Opportunities
    - 3.6.3.1 Untapped potential for emerging markets

## **CHAPTER 4: GENE THERAPY APPROACH**

### **4.1 OVERVIEW**

### **4.2 IN VIVO APPROACH**

### **4.3 EX VIVO APPROACH**

## **CHAPTER 5: GENE THERAPY MARKET, BY VECTOR TYPE**

### **5.1 OVERVIEW**

#### **5.1.1 Market size and forecast**

### **5.2 VIRAL VECTORS**

#### **5.2.1 Key market trends**

#### **5.2.2 Key growth factors and opportunities**

#### **5.2.3 Market size and forecast 50-51**

#### **5.2.4 Market size and forecast by country**

#### **5.2.5 Adenovirus**

#### **5.2.6 Lentivirus**

#### **5.2.7 Adeno-Associated Virus**

#### **5.2.8 Retrovirus**

#### **5.2.9 Herpes Simplex Virus**

#### **5.2.10 Poxvirus**

#### **5.2.11 Vaccinia Virus**

#### **5.2.12 Others 59-60**

### **5.3 NON-VIRAL VECTORS**

#### **5.3.1 Key market trends**

#### **5.3.2 Key growth factors and opportunities**

#### **5.3.3 Market size and forecast 62-63**

#### **5.3.4 Market size and forecast by country**

#### **5.3.5 Naked Plasmid Vector**

#### **5.3.6 Electroporation 66-67**

#### **5.3.7 Gene Gun**

#### **5.3.8 Lipofection 69-70**

#### **5.3.9 Others 71-72**

## **CHAPTER 6: GENE THERAPY MARKET, BY GENE TYPE**

### **6.1 OVERVIEW**

#### **6.1.1 Market size and forecast 73-74**

### **6.2 ANTIGEN**

- 6.2.1 Market size and forecast
- 6.2.2 Market size and forecast by country
- 6.3 CYTOKINE 77-78
  - 6.3.1 Market size and forecast
  - 6.3.2 Market size and forecast by country
- 6.4 TUMOR SUPPRESSOR 80-82
  - 6.4.1 Market size and forecast
  - 6.4.2 Market size and forecast by country
- 6.5 SUICIDE 84-85
  - 6.5.1 Market size and forecast
  - 6.5.2 Market size and forecast by country
- 6.6 DEFICIENCY
  - 6.6.1 Market size and forecast
  - 6.6.2 Market size and forecast by country
- 6.7 GROWTH FACTORS 89-91
  - 6.7.1 Market size and forecast
  - 6.7.2 Market size and forecast by country
- 6.8 RECEPTORS
  - 6.8.1 CAR T-Cell and Gene Therapy
    - 6.8.3.1 Introduction and Process
    - 6.8.3.2 Applications and Limitations 94-95
    - 6.8.3.3 Approved Products and Clinical Trials
    - 6.8.3.4 Market and Industry Trends
  - 6.8.2 Market size and forecast
  - 6.8.3 Market size and forecast by country
- 6.9 OTHERS
  - 6.9.1 Market size and forecast
  - 6.9.2 Market size and forecast by country

## **CHAPTER 7: GENE THERAPY MARKET, BY APPLICATION**

- 7.1 OVERVIEW
  - 7.1.1 Market size and forecast
- 7.2 ONCOLOGICAL DISORDERS 106-108
  - 7.2.1 Market size and forecast
  - 7.2.2 Market size and forecast by country
- 7.3 RARE DISEASES 110-114
  - 7.3.1 Market size and forecast
  - 7.3.2 Market size and forecast by country

## 7.4 CARDIOVASCULAR DISEASES

### 7.4.1 Market size and forecast

### 7.4.2 Market size and forecast by country

## 7.5 NEUROLOGICAL DISORDERS

### 7.5.1 Market size and forecast

### 7.5.2 Market size and forecast by country

## 7.6 INFECTIOUS DISEASE

### 7.6.1 Market size and forecast

### 7.6.2 Market size and forecast by country

## 7.7 OTHER DISEASES

### 7.7.1 Market size and forecast

### 7.7.2 Market size and forecast by country

# CHAPTER 8: GENE THERAPY MARKET, BY REGION

## 8.1 OVERVIEW

### 8.1.1 Market size and forecast

## 8.2 NORTH AMERICA

### 8.2.1 Key market trends

### 8.2.2 Key growth factors and opportunities

### 8.2.3 Market size and forecast, by country

### 8.2.4 Market size and forecast, by vector type

### 8.2.5 Market size and forecast, by gene type

### 8.2.6 Market size and forecast, by application

#### 8.2.6.1 U.S. market size and forecast, by vector type

#### 8.2.6.2 U.S. market size and forecast, by gene type

#### 8.2.6.3 U.S. market size and forecast, by application

#### 8.2.6.4 Canada market size and forecast, by vector type

#### 8.2.6.5 Canada market size and forecast, by gene type

#### 8.2.6.6 Canada market size and forecast, by application

#### 8.2.6.7 Mexico market size and forecast, by vector type

#### 8.2.6.8 Mexico market size and forecast, by gene type

#### 8.2.6.9 Mexico market size and forecast, by application

## 8.3 EUROPE

### 8.4.1 Key market trends

### 8.4.2 Key growth factors and opportunities

### 8.4.3 Market size and forecast, by country

### 8.4.4 Market size and forecast, by vector type

### 8.4.5 Market size and forecast, by gene type

#### 8.4.6 Market size and forecast, by application

8.3.6.1 Germany market size and forecast, by vector type

8.3.6.2 Germany market size and forecast, by gene type

8.3.6.3 Germany market size and forecast, by application

8.3.6.4 France market size and forecast, by vector type

8.3.6.5 France market size and forecast, by gene type

8.3.6.6 France market size and forecast, by application

8.3.6.7 UK market size and forecast, by vector type

8.3.6.8 UK market size and forecast, by gene type

8.3.6.9 UK market size and forecast, by application

8.3.6.10 Italy market size and forecast, by vector type

8.3.6.11 Italy market size and forecast, by gene type

8.3.6.12 Italy market size and forecast, by application

8.3.6.13 Spain market size and forecast, by vector type

8.3.6.14 Spain market size and forecast, by gene type

8.3.6.15 Spain market size and forecast, by application

8.3.6.16 Rest of Europe market size and forecast, by vector type

8.3.6.17 Rest of Europe market size and forecast, by gene type

8.3.6.18 Rest of Europe market size and forecast, by application

#### 8.4 ASIA-PACIFIC

##### 8.4.1 Key market trends

##### 8.4.2 Key growth factors and opportunities

##### 8.4.3 Market size and forecast, by country

##### 8.4.4 Market size and forecast, by vector type

##### 8.4.5 Market size and forecast, by gene type

##### 8.4.6 Market size and forecast, by application

8.4.6.1 Japan market size and forecast, by vector type

8.4.6.2 Japan market size and forecast, by gene type

8.4.6.3 Japan market size and forecast, by application

8.4.6.4 China market size and forecast, by vector type

8.4.6.5 China market size and forecast by gene type

8.4.6.6 China market size and forecast, by application

8.4.6.7 India market size and forecast, by vector type

8.4.6.8 India market size and forecast, by gene type

8.4.6.9 India market size and forecast, by application

8.4.6.10 South Korea market size and forecast, by vector type

8.4.6.11 South Korea market size and forecast, by gene type

8.4.6.12 South Korea market size and forecast, by application

8.4.6.13 Rest of Asia-Pacific market size and forecast, by vector type

8.4.6.14 Rest of Asia-Pacific market size and forecast, by gene type

8.4.6.15 Rest of Asia-Pacific market size and forecast, by application

## 8.5 LAMEA

8.5.1 Key market trends

8.5.2 Key growth factors and opportunities

8.5.3 Market size and forecast, by country

8.5.4 Market size and forecast, by vector type

8.5.5 Market size and forecast, by gene type

8.5.6 Market size and forecast, by application

8.5.6.1 Brazil market size and forecast by vector type

8.5.6.2 Brazil market size and forecast, by gene type

8.5.6.3 Brazil market size and forecast, by application

8.5.6.4 South Africa market size and forecast, by vector type

8.5.6.5 South Africa market size and forecast, by gene type

8.5.6.6 South Africa market size and forecast, by application

8.5.6.7 Rest of LAMEA market size and forecast by vector type

8.5.6.8 Rest of LAMEA market size and forecast, by gene type

8.5.6.9 Rest of LAMEA market size and forecast, by application

## CHAPTER 9: CLINICAL TRIALS ANALYSIS & PRODUCT PROFILES

### 9.1 OVERVIEW

### 9.2 CLINICAL TRIALS FROM 1989 TO 2018

9.2.1 Clinical Trials from 1989 to 2018: Based on Vector Type

9.2.2 Clinical Trials from 1989 to 2018: Based on Gene Type

9.2.3 Clinical Trials from 1989 to 2018: Based on Application

9.2.4 Clinical Trials from 1989 to 2018: Based on Region

### 9.3 CLINICAL TRIALS IN 2019

### 9.4 EXPECTED APPROVALS AND PIPELINE 177-178

### 9.5 APPROVED PRODUCTS PROFILES

9.5.1 GENDICINE

9.5.2 ONCORINE

9.5.3 REXIN-G

9.5.4 NEOVASCULGEN

9.5.5 GLYBERA

9.5.6 IMLYGIC

9.5.7 ZALMOXIS

9.5.8 STRIMVELIS

9.5.9 LUXTURN A

- 9.5.10 KYMRIAHA
- 9.5.11 YESCARTA
- 9.5.12 INVOSSA
- 9.5.13 ZOLGENSMA
- 9.5.14 ZYNTEGLO
- 9.5.15 COLLAGENE

## **CHAPTER 10: COMPANY PROFILES**

### **10.1 KEY MARKET PLAYERS**

- 10.1.1. Adaptimmune Therapeutics Plc 187-188
- 10.1.2. Abeona Therapeutics Inc. 189-190
- 10.1.3. Adverum Biotechnologies, Inc. 191-192
- 10.1.4. Applied Genetic Technologies Corporation 193-194
- 10.1.5. Arbutus Biopharma Corporation 195-196
- 10.1.6. Audentes Therapeutics Inc.
- 10.1.7. Avexis Inc.
- 10.1.8. Anchiano Therapeutics, Inc.
- 10.1.9. Bluebird Bio, Inc. 200-201
- 10.1.10. Celgene Corporation 202-203
- 10.1.11. CRISPR Therapeutics AG
- 10.1.12. Editas Medicine, Inc.
- 10.1.13. Gilead Sciences, Inc. (Kite Pharma, Inc.) 206-207
- 10.1.14. GlaxoSmithKline Plc 208-209
- 10.1.15. Intellia Therapeutics Inc.
- 10.1.16. Merck & Co., Inc. 211-212
- 10.1.17. Novartis AG 213-214
- 10.1.18. Regeneron, Inc. 215-216
- 10.1.19. Sangamo Therapeutics, Inc. 217-218
- 10.1.20. Spark Therapeutics, Inc. 219-220
- 10.1.21. Uniqure N.V. 221-222
- 10.1.22. Voyager Therapeutics, Inc. 223-224

### **10.2 OTHER COMPANY PROFILES**

- 10.2.1. 4D Molecular Therapeutics
- 10.2.2. Advantagene, Inc.
- 10.2.3. Akouos, Inc.
- 10.2.4. Allogene Therapeutics, Inc.
- 10.2.5. Amgen, Inc.
- 10.2.6. American Gene Technologies International Inc.

- 10.2.7. Amicus Therapeutics, Inc.
- 10.2.8. Angas MG, Inc.
- 10.2.9. Arrowhead Pharmaceuticals, Inc.
- 10.2.10. Asklepios Biopharmaceutical, Inc.
- 10.2.11. AstraZeneca Plc
- 10.2.12. Atara Biotherapeutics, Inc.
- 10.2.13. Avrobio, Inc.
- 10.2.14. Bayer AG
- 10.2.15. Benitec Biopharma Limited
- 10.2.16. Biogen Inc.
- 10.2.17. Biomarin Pharmaceutical, Inc.
- 10.2.18. Bristol-Myers Squibb Company
- 10.2.19. Carsgen Therapeutics, Ltd
- 10.2.20. Casebia Therapeutics
- 10.2.21. Cellectis SA
- 10.2.22. Celyad SA
- 10.2.23. Curevac AG
- 10.2.24. Fibrocell Science Inc.
- 10.2.25. Freeline Therapeutics, Ltd.
- 10.2.26. Gensight Biologics S.A.
- 10.2.27. Intrexon Corporation
- 10.2.28. Oxford Biomedica Plc

## **CHAPTER 11: CONCLUSION & STRATEGIC RECOMMENDATIONS**

### **11.1 STRATEGIC RECOMMENDATIONS 253-254**

### **11.2 CONCLUSION**

## List Of Tables

### LIST OF TABLES

TABLE NO.1 LIST OF MENTIONED ORGANIZATIONS AND COMPANIES

TABLE NO.2 GENE THERAPY MARKET SCOPE

TABLE NO.3 GLOBAL GENE THERAPY MARKET BY VECTOR TYPE 2018-2026  
(\$MILLION)

TABLE NO.4 GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY  
REGION, 2018-2026 (\$MILLION)

TABLE NO.5 GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,  
2018-2026 (\$MILLION)

TABLE NO.6 VIRAL VECTOR CHARACTERISTICS

TABLE NO.7 GLOBAL GENE THERAPY MARKET FOR NON VIRAL VECTORS, BY  
REGION, 2018-2026 (\$MILLION)

TABLE NO.8 GLOBAL GENE THERAPY MARKET FOR NON VIRAL VECTORS, BY  
TYPE, 2018-2026 (\$MILLION)

TABLE NO.9 OVERVIEW OF DIFFERENT NON-VIRAL VECTOR DELIVERY

TABLE NO.10 GLOBAL GENE THERAPY, BY GENE TYPE, 2018-2026 (\$MILLION)

TABLE NO.11 ANTIGEN GENE THERAPY MARKET, BY REGION, 2018-2026  
(\$MILLION)

TABLE NO.12 CYTOKINES AS CANCER GENE THERAPY

TABLE NO.13 CYTOKINE GENE THERAPY MARKET, BY REGION, 2018-2026  
(\$MILLION)

TABLE NO.14 TUMOR SUPPRESSOR BASED GENE THERAPY CANDIDATES

TABLE NO.15 TUMOR SUPPRESSOR GENES BY TYPES

TABLE NO.16 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION,  
2018-2026 (\$MILLION)

TABLE NO.17 SUICIDE GENE THERAPY MARKET, BY REGION, 2018-2026  
(\$MILLION)

TABLE NO.18 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2018-2026  
(\$MILLION)

TABLE NO.19 MAJOR GROWTH FACTOR FAMILIES, SOURCES AND ACTIONS

TABLE NO.20 GROWTH FACTORS GENE THERAPY MARKET, BY REGION,  
2018-2026 (\$MILLION)

TABLE NO.21 RECEPTORS GENE THERAPY MARKET, BY REGION, 2018-2026  
(\$MILLION)

TABLE NO.22 SUMMARY OF MAJOR ONCOLYTIC VIRUSES UNDER CLINICAL  
DEVELOPMENT

TABLE NO.23 LIST OF FEW DNA REPLICATION INHIBITORS

TABLE NO.24 GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.25 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2018-2026 (\$MILLION)

TABLE NO.26 LIST OF APPROVED GENE THERAPIES FOR CANCER

TABLE NO.27 LIST OF EXPECTED GENE THERAPY APPROVALS FOR CANCER INDICATIONS

TABLE NO.28 GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.29 LIST OF APPROVED GENE THERAPIES FOR RARE DISEASES

TABLE NO.30 LIST OF EXPECTED APPROVALS FOR RARE DISEASES INDICATIONS

TABLE NO.31 GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.32 LIST OF EXPECTED GENE THERAPY APPROVALS FOR CARDIOVASCULAR DISEASES INDICATIONS

TABLE NO.33 GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.34 LIST OF EXPECTED GENE THERAPY APPROVALS FOR NEUROLOGICAL DISORDERS INDICATIONS

TABLE NO.35 GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.36 GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.37 LIST OF EXPECTED GENE THERAPY APPROVALS FOR DERMATOLOGICAL AND OPHTHALMOLOGICAL INDICATIONS

TABLE NO.38 GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.39 GENE THERAPY MARKET, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.40 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2018-2026 (\$MILLION)

TABLE NO.41 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 (\$MILLION)

TABLE NO.42 NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 (\$MILLION)

TABLE NO.43 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 (\$MILLION)

TABLE NO.44 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.45 U.S. GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.46 U.S. GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.47 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.48 CANADA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.49 CANADA GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.50 MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.51 MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.52 MEXICO GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.53 EUROPE GENE THERAPY MARKET, BY COUNTRY, 2018-2026

(\$MILLION)

TABLE NO.54 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.55 EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.56 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.57 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.58 GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.59 GERMANY GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.60 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.61 FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.62 FRANCE GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.63 UK GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.64 UK GENE THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.65 UK GENE THERAPY MARKET, BY APPLICATION, 2018-2026  
(\$MILLION)

TABLE NO.66 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026  
(\$MILLION)

TABLE NO.67 ITALY GENE THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.68 ITALY GENE THERAPY MARKET, BY APPLICATION, 2018-2026  
(\$MILLION)

TABLE NO.69 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026  
(\$MILLION)

TABLE NO.70 SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.71 SPAIN GENE THERAPY MARKET, BY APPLICATION, 2018-2026  
(\$MILLION)

TABLE NO.72 REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE,  
2018-2026 (\$MILLION)

TABLE NO.73 REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE,  
2018-2026 (\$MILLION)

TABLE NO.74 REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION,  
2018-2026 (\$MILLION)

TABLE NO.75 ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2018-2026  
(\$MILLION)

TABLE NO.76 ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE,  
2018-2026 (\$MILLION)

TABLE NO.77 ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.78 ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION,  
2018-2026 (\$MILLION)

TABLE NO.79 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026  
(\$MILLION)

TABLE NO.80 JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.81 JAPAN GENE THERAPY MARKET, BY APPLICATION, 2018-2026  
(\$MILLION)

TABLE NO.82 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026  
(\$MILLION)

TABLE NO.83 CHINA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.84 CHINA GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.85 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.86 INDIA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.87 INDIA GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.88 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE,  
2018-2026 (\$MILLION)

TABLE NO.89 SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE,  
2018-2026 (\$MILLION)

TABLE NO.90 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION,  
2018-2026 (\$MILLION)

TABLE NO.91 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR  
TYPE, 2018-2026 (\$MILLION)

TABLE NO.92 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE,  
2018-2026 (\$MILLION)

TABLE NO.93 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY  
APPLICATION, 2018-2026 (\$MILLION)

TABLE NO.94 LAMEA GENE THERAPY MARKET, BY COUNTRY, 2018-2026  
(\$MILLION)

TABLE NO.95 LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026  
(\$MILLION)

TABLE NO.96 LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.97 LAMEA GENE THERAPY MARKET, BY APPLICATION, 2018-2026  
(\$MILLION)

TABLE NO.98 BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026  
(\$MILLION)

TABLE NO.99 BRAZIL THERAPY MARKET, BY GENE TYPE, 2018-2026 (\$MILLION)

TABLE NO.100 BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2018-2026  
(\$MILLION)

TABLE NO.101 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE,  
2018-2026 (\$MILLION)

TABLE NO.102 SOUTH AFRICA THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.103 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION,

2018-2026 (\$MILLION)

TABLE NO.104 REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE,  
2018-2026 (\$MILLION)

TABLE NO.105 REST OF LAMEA THERAPY MARKET, BY GENE TYPE, 2018-2026  
(\$MILLION)

TABLE NO.106 REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION,  
2018-2026 (\$MILLION)

TABLE NO.107 NUMBER OF CLINICAL TRIALS BASED ON VECTOR TYPE,  
1989-2018

TABLE NO.108 NUMBER OF CLINICAL TRIALS BASED ON GENE TYPE, 1989-2018

TABLE NO.109 NUMBER OF CLINICAL TRIALS BASED ON APPLICATION,  
1989-2018

TABLE NO.110 NUMBER OF CLINICAL TRIALS BASED ON REGION, 1989-2018

TABLE NO.111 BREAK DOWN OF 30, PHASE 3 CLINICAL TRIALS BASED ON  
INDICATION AREA, Q2 2019

TABLE NO.112 LIST OF 30 PHASE 3, GENE THERAPY CANDIDATES IN CLINICAL  
TRIALS, Q2 2019

TABLE NO.113 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT

TABLE NO.114 ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT

TABLE NO.115 ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO

TABLE NO.116 ABEONA THERAPEUTICS INC.: COMPANY SNAPSHOT

TABLE NO.117 ABEONA THERAPEUTICS INC.: PRODUCT CATEGORY

TABLE NO.118 ABEONA THERAPEUTICS INC.: PRODUCT PORTFOLIO

TABLE NO.119 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT

TABLE NO.120 ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT CATEGORY

TABLE NO.121 ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT PORTFOLIO

TABLE NO.122 APPLIED GENETIC TECHNOLOGIES CORPORATION: COMPANY  
SNAPSHOT

TABLE NO.123 APPLIED GENETIC TECHNOLOGIES CORPORATION: OPERATING  
SEGMENTS

TABLE NO.124 APPLIED GENETIC TECHNOLOGIES CORPORATION: PRODUCT  
PORTFOLIO

TABLE NO.125 ARBUTUS BIOPHARMA CORPORATION: COMPANY SNAPSHOT

TABLE NO.126 ARBUTUS BIOPHARMA CORPORATION: PRODUCT PORTFOLIO

TABLE NO.127 AUDENTES THERAPEUTICS INC.: COMPANY SNAPSHOT

TABLE NO.128 AUDENTES THERAPEUTICS INC.: PRODUCT PORTFOLIO

TABLE NO.129 AVEXIS INC.: COMPANY SNAPSHOT

TABLE NO.130 AVEXIS INC.: PRODUCT PORTFOLIO

TABLE NO.131 ANCHIANO THERAPEUTICS, INC.: COMPANY SNAPSHOT

|              |                              |                    |
|--------------|------------------------------|--------------------|
| TABLE NO.132 | ANCHIANO THERAPEUTICS, INC.: | PRODUCT CATEGORY   |
| TABLE NO.133 | ANCHIANO THERAPEUTICS, INC.: | PRODUCT PORTFOLIO  |
| TABLE NO.134 | BLUEBIRD BIO, INC.:          | COMPANY SNAPSHOT   |
| TABLE NO.135 | BLUEBIRD BIO, INC.:          | PRODUCT CATEGORY   |
| TABLE NO.136 | BLUEBIRD BIO, INC.:          | PRODUCT PORTFOLIO  |
| TABLE NO.137 | CELGENE CORPORATION:         | COMPANY SNAPSHOT   |
| TABLE NO.138 | CELGENE CORPORATION:         | OPERATING SEGMENTS |
| TABLE NO.139 | CELGENE CORPORATION:         | PRODUCT PORTFOLIO  |
| TABLE NO.140 | CRISPR THERAPEUTICS AG:      | COMPANY SNAPSHOT   |
| TABLE NO.141 | CRISPR THERAPEUTICS AG:      | PRODUCT PORTFOLIO  |
| TABLE NO.142 | EDITAS MEDICINE, INC.:       | COMPANY SNAPSHOT   |
| TABLE NO.143 | EDITAS MEDICINE, INC.:       | PRODUCT PORTFOLIO  |
| TABLE NO.144 | GILEAD SCIENCES. INC.:       | COMPANY SNAPSHOT   |
| TABLE NO.145 | GILEAD SCIENCES. INC.:       | OPERATING SEGMENTS |
| TABLE NO.146 | GILEAD SCIENCES. INC.:       | PRODUCT PORTFOLIO  |
| TABLE NO.147 | GLAXOSMITHKLINE PLC:         | COMPANY SNAPSHOT   |
| TABLE NO.148 | GLAXOSMITHKLINE PLC:         | OPERATING SEGMENTS |
| TABLE NO.149 | GLAXOSMITHKLINE PLC:         | PRODUCT PORTFOLIO  |
| TABLE NO.150 | INTELLIA THERAPEUTICS INC.:  | COMPANY SNAPSHOT   |
| TABLE NO.151 | INTELLIA THERAPEUTICS INC.:  | PRODUCT PORTFOLIO  |
| TABLE NO.152 | MERCK & CO.,INC.:            | COMPANY SNAPSHOT   |
| TABLE NO.153 | MERCK & CO.,INC.:            | OPERATING SEGMENTS |
| TABLE NO.154 | MERCK & CO.,INC.:            | PRODUCT PORTFOLIO  |
| TABLE NO.155 | NOVARTIS AG:                 | COMPANY SNAPSHOT   |
| TABLE NO.156 | NOVARTIS AG:                 | OPERATING SEGMENTS |
| TABLE NO.157 | NOVARTIS AG:                 | PRODUCT PORTFOLIO  |
| TABLE NO.158 | REGENXBIO, INC.:             | COMPANY SNAPSHOT   |
| TABLE NO.159 | REGENXBIO, INC.:             | PRODUCT PORTFOLIO  |
| TABLE NO.160 | SANGAMO THERAPEUTICS, INC.:  | COMPANY SNAPSHOT   |
| TABLE NO.161 | SANGAMO THERAPEUTICS, INC.:  | OPERATING SEGMENTS |
| TABLE NO.162 | SANGAMO THERAPEUTICS, INC.:  | PRODUCT PORTFOLIO  |
| TABLE NO.163 | SPARK THERAPEUTICS, INC.:    | COMPANY SNAPSHOT   |
| TABLE NO.164 | SPARK THERAPEUTICS, INC.:    | OPERATING SEGMENTS |
| TABLE NO.165 | SPARK THERAPEUTICS, INC.:    | PRODUCT PORTFOLIO  |
| TABLE NO.166 | UNIQUE N.V.:                 | COMPANY SNAPSHOT   |
| TABLE NO.167 | UNIQUE N.V.:                 | OPERATING SEGMENTS |
| TABLE NO.168 | UNIQUE N.V.:                 | PRODUCT PORTFOLIO  |
| TABLE NO.169 | VOYAGER THERAPEUTICS, INC.:  | COMPANY SNAPSHOT   |
| TABLE NO.170 | VOYAGER THERAPEUTICS, INC.:  | OPERATING SEGMENTS |

TABLE NO.171 VOYAGER THERAPEUTICS, INC.: PRODUCT PORTFOLIO

## List Of Figures

### LIST OF FIGURES

FIGURE NO.1 GENE THERAPY MARKET SEGMENTS

FIGURE NO.2 GENE THERAPY CLINICAL TRIALS AT THE END OF Q2 2019

FIGURE NO.3 MERGERS AND ACQUISITIONS, BY VOLUME, 2016-2018\*

FIGURE NO.4 TOP INVESTMENT POCKETS: BY GENE TYPE, 2018

FIGURE NO.5 BARGAINING POWER OF BUYERS

FIGURE NO.6 BARGAINING POWER OF SUPPLIERS

FIGURE NO.7 THREAT OF NEW ENTRANTS

FIGURE NO.8 THREAT OF SUBSTITUTION

FIGURE NO.9 COMPETITIVE RIVALRY

FIGURE NO.10 RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY

FIGURE NO.11 IN VIVO AND EX VIVO GENE THERAPY

FIGURE NO.12 SYSTEMATIC AND TARGETED IN VIVO APPROACH

FIGURE NO.13 EX-VIVO GENE THERAPY EXPLANATION

FIGURE NO.14 EX-VIVO VS IN-VIVO GENE THERAPY: BREAKDOWN OF PIPELINE, 2018

FIGURE NO.15 VIRAL VECTOR VS NON-VIRAL VECTOR: BREAKDOWN OF PIPELINE, 2018

FIGURE NO.16 GLOBAL GENE THERAPY MARKET TREND BY VECTOR TYPE 2018-2026 (\$MILLION)

FIGURE NO.17 BREAKDOWN OF MARKET SHARE OF VIRAL VECTORS ON THE BASIS OF TYPE

FIGURE NO.18 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2018 VS 2026 (%)

FIGURE NO.19 ADENOVIRUS STRUCTURE

FIGURE NO.20 RETROVIRUS VECTOR EDITING

FIGURE NO.21 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR NON VIRAL VECTORS, 2018 VS 2026 (%)

FIGURE NO.22 INOVIO'S ELECTROPORATION DEVICE CELECTRA

FIGURE NO.23 MECHANISM OF PLASMID DNA DELIVERY BY CELLECTRA

FIGURE NO.24 GLOBAL GENE THERAPY TREND, BY GENE TYPE, 2018-2026 (\$MILLION)

FIGURE NO.25 COMPARATIVE REGIONAL SHARE ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.26 COMPARATIVE REGIONAL SHARE ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.27 COMPARATIVE REGIONAL SHARE ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.28 COMPARATIVE REGIONAL SHARE ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.29 COMPARATIVE REGIONAL SHARE ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.30 COMPARATIVE REGIONAL SHARE ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.31 INTRACELLULAR CELL SIGNALING

FIGURE NO.32 CAR T-CELL PROCESS

FIGURE NO.33 SHARE OF CAR T-CELL TRIALS TARGETING CD19, 2018

FIGURE NO.34 GLOBAL CAR T-CELL THERAPY CLINICAL TRIALS, BY NUMBERS, 2007-2018

FIGURE NO.35 GLOBAL DISTRIBUTION OF CAR T-CELL THERAPEUTIC COMPANIES, 2018

FIGURE NO.36 COMPARATIVE REGIONAL SHARE ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.37 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2018 VS 2026 (%)

FIGURE NO.38 BREAK DOWN OF GENE THERAPY CLINICAL TRIALS, BY DISEASE INDICATION, 2018

FIGURE NO.39 NO. OF GENE THERAPY CLINICAL TRIALS, BY CANCER TYPES, 2018

FIGURE NO.40 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2018 VS 2026

FIGURE NO.41 GENE THERAPY CLINICAL TRIALS BREAK DOWN, BY RARE DISEASES, 2018

FIGURE NO.42 BREAK DOWN OF RARE DISEASE CLINICAL TRIALS, BY DISEASE INDICATION, 2018

FIGURE NO.43 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2018 VS 2026 (%)

FIGURE NO.44 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2018 VS 2026 (%)

FIGURE NO.45 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2018 VS 2026

FIGURE NO.46 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2018 VS 2026 (%)

FIGURE NO.47 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2018 VS 2026 (%)

FIGURE NO.48 GENE THERAPY CLINICAL TRIALS APPROVED WORLDWIDE FROM 1989-2018

FIGURE NO.49 COMPARISON OF VIRAL VS NON VIRAL CLINICAL TRIALS , 1989-2018

FIGURE NO.50 CLINICAL TRIALS BASED ON GENE TYPE, 1989-2018

FIGURE NO.51 CLINICAL TRIALS BASED ON APPLICATION, 1989-2018

FIGURE NO.52 CLINICAL TRIALS BASED ON REGION, 1989-2018

FIGURE NO.53 GENE THERAPY CLINICAL TRIALS AT THE END OF Q2 2019

FIGURE NO.54 ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.55 ABEONA THERAPEUTICS INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.56 ADVERUM BIOTECHNOLOGIES, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.57 AGTC: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.58 ARBUTUS BIOPHARMA CORPORATION.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.59 BLUEBIRD BIO, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.60 CELGENE CORPORATION: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.61 GILEAD SCIENCES. INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.62 GILEAD SCIENCES. INC.: REVENUE, BY GEOGRAPHY 2018 (%)

FIGURE NO.63 GSK PLC: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.64 GSK PLC: REVENUE BY GEOGRAPHY AND PRODUCT SEGMENT 2018 (%)

FIGURE NO.65 MERCK & CO.,INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.66 MERCK & CO.,INC.:REVENUE BY GEOGRAPHY & PRODUCT SEGMENT 2018(%)

FIGURE NO.67 NOVARTIS AG: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.68 NOVARTIS AG: REVENUE BY GEOGRAPHY AND PRODUCT SEGMENT 2018 (%)

FIGURE NO.69 REGENXBIO, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.70 SANGAMO THERAPEUTICS, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.71 SPARK THERAPEUTICS, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.72 UNIQUE N.V.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.73 VOYAGER THERAPEUTICS, INC.: REVENUE, 2016-2018 (\$MILLION)

## I would like to order

Product name: Gene Therapy Market: 2019-2026 - Market Analysis and Forecast

Product link: <https://marketpublishers.com/r/GBCD599E6295EN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBCD599E6295EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970